en Pediatric Hematology & Oncology Pediatric Hematology & Oncology پژوهشي Original Article <p style="text-align: justify;"><span style="line-height:2;"><span style="font-size:14px;"><span style="font-family:Arial;"><span style="unicode-bidi:embed"><b>Background:</b> This study aimed to investigate <span style="background:white"><span style="color:black">the protective role of deferoxamine (DFO) in the prevention of doxorubicin (DOX)-induced hepatic fibrosis in children.</span></span></span><br> <span style="unicode-bidi:embed"><b>Methods:</b> In this prospective randomized controlled trial, 61 treatment-na&iuml;ve children (2-18 years) with different types of cancer who referred to a tertiary teaching hospital in the South of Iran were enrolled. They were randomly assigned to 3 groups; group 1 (control, n=21), group 2 (DFO 10 times DOX dose, n=20), group 3 (DFO 50mg/kg, n=20). DFO was administered as an 8-hour continuous intravenous infusion during and after DOX infusion in each chemotherapy cycle. Non-invasive serum markers of liver fibrosis, including <span style="background:white"><span style="color:black">AST-to-platelet ratio&nbsp;<em><span calibri="">index</span></em>&nbsp;(<em><span calibri="">APRI</span></em>)</span></span>, <span style="background:white"><span style="color:black">Fibrosis-</span></span><span style="background:white"><span style="color:#4d5156">4 (</span></span>FIB-4) score and Fibro Test were measured in each individual. Besides, hepatic Fibro Scan was used after the last course of chemotherapy to estimate the fibrosis degree.</span><br> <span style="unicode-bidi:embed"><b>Results:</b> Alanine aminotransferase was mildly increased after treatment compared to before treatment. The treatment with DFO 10 times DOX dose was associated with a significant decline in post-treatment APRI (adjusted odds ratio 0.17; 95% confidence interval 0.03- 0.84. P-value=0.015). The METAVIR fibro scores were in the F0-F1 zone in all participants, and the results were comparable in study groups. No adverse drug effects were reported in the treatment groups.</span><br> <span style="unicode-bidi:embed"><b>Conclusion:</b> DOX may not lead to severe liver fibrosis if the maximum cumulative dose allowed is not exceeded. DFO at the dose of 10 times of DOX dose may have a potential protective role against liver fibrosis. More studies with longer follow-up are needed to <span style="background:white"><span style="color:black">further assess this issue. </span></span></span></span></span></span></p> Deferoxamine, Doxorubicin, Hepatic fibrosis, Children 1 10 http://ijbc.ir/browse.php?a_code=A-10-776-1&slc_lang=en&sid=1 Mohammadreza Bordbar mbordbar53@gmail.com 10031947532846008937 10031947532846008937 No Hematology Research center, Shiraz University of Medical Sciences, Shiraz, Iran Gholamreza Fathpour dr.reza.fathpour@gmail.com 10031947532846008938 10031947532846008938 Yes Hematology Research center, Shiraz University of Medical Sciences, Shiraz, Iran Seyed Mohsen Dehghani dehghanism@gmail.com 10031947532846008939 10031947532846008939 No Medical sciences دانشگاه شیراز Sezaneh Haghpanah sezanehhaghpanah@gmail.com 10031947532846008940 10031947532846008940 No Shiraz Uni Hossein Molavi Vardanjani hosseinmolavi@ymail.com 10031947532846008941 10031947532846008941 No Shiraz Uni Mohammadreza Fattahi fattahim38@yahoo.com 10031947532846008942 10031947532846008942 No Shiraz uni Mahdi Shahriari shahryar@sums.ac.ir 10031947532846008943 10031947532846008943 No shiraz uni Nader Shakibazad Nshakibazad@gmail.com 10031947532846008944 10031947532846008944 No shiraz uni